This is a preview of subscription content, log in via an institution to check access.
Literatur
Gold MR, Siegel JE, Russel LE et al. eds. Cost-effectiveness in health and medicine. New York, NY: Oxford University, 1996.
Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160–8.
Hillner BE et al. Economic analysis of adjuvant interferon-alpha 2a in high risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;6:2351–8.
Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon-a-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.
Kochanek KD, Hudson BL. Advance report of final mortaility statistics, 1992. In: Monthly vital statistics report, Vol. 43. Hyattsville, MD: National Center for Health Statistics, 1995.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoffmann, W. Wirtschaftlichkeitsanalyse der adjuvanten Interferon-alpha-2b-Therapie bei Hochrisiko-Melanompatienten aufgrund von Ergebnissen der Studie ECOG 1684. Strahlenther Onkol 174, 288–289 (1998). https://doi.org/10.1007/BF03038725
Issue Date:
DOI: https://doi.org/10.1007/BF03038725